The Trump administration is delaying a voluntary model that aimed to expand access to GLP-1s in Part D after pushback from insurers. The Centers for Medicare & Medicaid Services first announced the ...
New research presented at this year's European Congress on Obesity in Istanbul, Turkey, shows that use of obesity drugs ...
A new study has found that an oral GLP-1 weight-loss medication called orforglipron (Foundayo) can help consumers maintain ...
Millions of older Americans may have access for the first time to obesity drugs at a low price of $50 a month starting in ...
Two peer-reviewed studies published in Obesity Pillars report that Ivim Health patients receiving GLP-1 therapy within a comprehensive care protocol achieved up to 26.54% average weight loss in ...
SHERIDAN, WY – Sermorelin.com, a telehealth platform specializing in physician-supervised peptide therapy, today announced the launch of a new clinical program designed to help patients on GLP-1 ...
Under the Bridge program, eligible beneficiaries can get Medicare coverage of GLP-1s for obesity for a $50 copay. Extending the short-term GLP-1 Bridge program is good news for eligible Medicare ...
Morning Overview on MSN
Review finds GLP-1 weight-loss drugs may cut Alzheimer’s amyloid and tau
Drugs best known for helping people lose weight may also chip away at the proteins that define Alzheimer’s disease. A ...
Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. In a new survey from Health, 76% of GLP-1 users said ...
GLP-1 use isn't just drastically changing the lives of those, like McDonald, who are on the weight-loss drug. It's changing ...
GLP-1 receptor agonist use remains low in people with multiple sclerosis despite high eligibility rates for diabetes and obesity indications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results